Advanced Filters
noise

Male Pattern Baldness Clinical Trials

A listing of Male Pattern Baldness medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 272 clinical trials
M Mathurin FUMERY

Reliability of IUS in Crohn's Disease

Transabdominal intestinal ultrasound (IUS) is gaining acceptance as a point-of-care test to objectively assess disease activity in Crohn's disease (CD). In order to incorporate individual parameters in a future definition of transmural healing, and for the consistent application of IUS as a modality to assess treatment outcomes and establish therapeutic …

18 years of age All Phase N/A
S Sainan Shu, PhD

Fecal Microbiota Transplantation in Pediatric Crohn's Disease

This study will test the safety and effectiveness of fecal microbiota transplantation (FMT) plus partial enteral nutrition (PEN) in refractory pediatric Crohn's disease (CD) who have failed conventional treatment

2 - 16 years of age All Phase N/A
D David Binion, MD

Autologous Stem Cell Transplantation for Crohn's Disease

The objective of this study is to evaluate the safety and effectiveness of administering high-dose chemotherapy followed by infusion of autologous CD34-selected peripheral blood stem cells (PBSC) in pediatric and adult patients with severe Crohn's disease.

10 - 60 years of age All Phase 1/2
J Jonathan Lagdameo

Autologous Stem Cell Transplant for Crohn's Disease

Crohn's Disease (CD) is an inflammatory bowel disease. It can lead to significant complications and discomfort in the stomach and intestines. Crohn's disease is a debilitating, incurable disease of immune cells; it affects almost 1 million people in the United States. CD is characterized by inflammation of the stomach and …

18 years of age All Phase 2
S Site Contact

Pharmacokinetic Infliximab Data in Pediatric Crohn's Disease

Rationale: Crohn's disease (CD) is a chronic, debilitating inflammatory bowel disease (IBD) which is diagnosed during childhood in up to one in ten patients. The use of anti-tumor necrosis factor (TNF)-α agents has significantly ameliorated CD management. Infliximab (IFX) is the first anti-TNF-α agent registered for pediatric CD. The current …

3 - 15 years of age All Phase 4
E Elina M Jokinen, PhD

Fecal Microbiota Transplantation in Postoperative Crohn's Disease

This pilot study aims to detect possible trends or signals suggesting efficacy of FMT on prevention of delay of POR, to determine the safety of FMT in post operative CD, and asses if a full randomised controlled trial is feasible in this setting. With microbiota analysis we aim to assess …

18 - 120 years of age All Phase N/A
J Jia Ke

Comparing Surgical Approaches for Crohn's Disease Recurrence

Despite significant advancements in the treatment of Crohn's disease (CD), approximately 50% of patients undergo surgical intervention within ten years of diagnosis. Furthermore, more than 70% of these patients experience endoscopic recurrence within one year after surgery. This subset of patients often faces a poorer long-term prognosis and requires long-term …

14 - 65 years of age All Phase N/A
B Byron Vaughn

Standardized Microbiota Transplant Therapy in Crohn's Disease

Crohn's disease (CD) develops because of a disruption of homeostasis between the gut microbiota and the host immune system resulting in excessive inflammation in the intestinal tract. Current drug therapies for CD are directed at the immune system. The emergence of fecal microbiota transplantation (FMT) for the treatment of recurrent …

18 - 89 years of age All Phase 2
C Clinical Research Coordinator

Partial-enteral Nutrition Protocol for Crohn's Disease

A novel dietary intervention combining a standardized IBD diet (IBD-AID) with supplementation from a pea protein plant-based oral nutrition supplement (ONS) (Kate Farms Peptide 1.5) to improve protein, calorie, and nutrient intake in adult patients experiencing a Crohn's disease flare starting new immunologic therapy. Additionally, this study will include objective …

18 years of age All Phase N/A

Risankizumab in Children With Crohn's Disease (RisaKids)

The goal of this observational study is to to prospectively explore the real life short (12 weeks) and longer term (54 weeks) clinical, biochemical and endoscopic outcomes of risankizumab in pediatric CD. This is a 1-year prospective multi-center cohort study of children commencing on risankizumab for pediatric CD with 2 …

6 - 18 years of age All Phase N/A

Simplify language using AI